NCT01341002

Brief Summary

The objective of this study is to estimate red blood cells (RBC) transfusion related to central venous O2 saturation (ScvO2) measurement. This prospective, randomized trial is performed in visceral, vascular and thoracic surgery units in the university hospital of Lille. One hundred patients need to be included. Inclusion criteria are: age 18 to 99 year old, patient with central venous catheter in place and fulfilling the haemoglobin (Hb) threshold criteria for RBC transfusion according to the XXIIIth French Consensus Conference in critical care medicine recommendations. After randomisation, patients will be eligible to receive RBC according to their level of Hb in the standard group and according to the Hb and ScvO2 in the optimization group. Patients without any disease are transfused if their Hb level is below 7g/dL; patients older than 60 years or having sepsis are transfused if their Hb level is 8g/dL or lower and cardiac patients are transfused if their Hb level is 9g/dL or lower. In the second group, transfusion is performed if and only if the ScvO2 level is les than 70% when Hb is under the same threshold levels. The primary aim of the study is to compare the number of RBC units transfused by group (standard group or optimization group) over a period of 5 days counted from the first decision of transfusion taken post-operative. Considering the randomisation and considering the 50 % reduction of the decisions of transfusion in the group optimization, the absolute blood savings is estimated 25 % for the whole population. Secondary end points include the number of side effects associated with transfusion or when avoiding transfusion, length of hospital stay, and hospital mortality as well as major adverse events.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2009

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2009

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

April 21, 2011

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 25, 2011

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2013

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2014

Completed
Last Updated

May 13, 2015

Status Verified

May 1, 2015

Enrollment Period

4 years

First QC Date

April 21, 2011

Last Update Submit

May 12, 2015

Conditions

Keywords

Postoperative Carered blood cell transfusionvenous oxygen saturation

Outcome Measures

Primary Outcomes (1)

  • Number of RBC units transfused by group

    to compare the number of RBC units transfused by group (standard group or optimization group) over a period of 5 days counted from the first decision of transfusion taken post-operative

    5 days

Study Arms (2)

SCVO2 < 70%

EXPERIMENTAL

guidelines transfusion + SCVO2 \< 70%

Procedure: Transfusion

currently intervention

ACTIVE COMPARATOR

guidelines transfusion

Procedure: Transfusion

Interventions

TransfusionPROCEDURE

Red Blood Cells (RBC) Transfusion if SCVO2 \< 70% and guidelines

SCVO2 < 70%

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • central venous catheter
  • anemia With reference to french consensus about transfusion

You may not qualify if:

  • intensive care
  • emergency transfusion
  • shock, hypovolemia
  • need to go under surgery into 4 hours
  • acute kidney injury or chronic renal disease
  • brain injury
  • pregnancy
  • heart disease : ischemia \<1 mois

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

university Hospital, lille

Lille, 59037, France

Location

MeSH Terms

Conditions

Postoperative Complications

Interventions

Blood Transfusion

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Biological TherapyTherapeutics

Study Officials

  • Benoît VALLET, PU-PH

    Lille University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 21, 2011

First Posted

April 25, 2011

Study Start

November 1, 2009

Primary Completion

November 1, 2013

Study Completion

May 1, 2014

Last Updated

May 13, 2015

Record last verified: 2015-05

Locations